Krishan Jethwa
@KrishanJethwa
GI Radiation Oncologist | Associate PD @MayoRadOnc @MayoClinic | Passions for #PatientCare, #MedEd, QoL, #PublicHealth, and #ClinicalTrials | Views are my own
🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you @ASCO for the opportunity!🙏🏽 1/
🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum @JAMAOnc
Can we safely & effectively add radiation to immunotherapy for patients with hepatocellular carcinoma (HCC) with portal vein thrombus (PVT)? @nithyamurthy09 & colleagues retrospectively report on 62 HCC with PVT patients treated with ☑️concurrent (within 6 weeks) immunotherapy…
Expanding the #radonc toolkit for ☢️necrosis (RN) tx after SRS for functional disorders In this case report, Boswellia serrata resolved RN in a pt w/ steroid-refractory RN after SRS (80 Gy) for OCD Should Boswellia be a 1st line tx for RN after SRS? advancesradonc.org/article/S2452-…
Are you an oncologist with interest in GI cancer? If so, are you interested in joining a growing academic GI Oncology practice in Rochester, MN? We have 13 GI oncs with additional 3 joining soon and still growing 😀 We are hiring! PM me if interested. jobs.mayoclinic.org/job/rochester/…
❗️Out now: tinyurl.com/ycxku7pr❗️ In this Ph II trial (n=26), addition of IO (before, during, after) to definitive chemo☢️for pts w/ LA p16+ OPCs (cT4/3, matted LN, cENE) had: 🔘 2yr PFS: 65% (vs 68% historic control) 🔘 G3+ acute dysphagia: 54% 🔘 Incomplete IO course: 68%…
❗️OUT NOW - Dosi predictors of toxicity on PROMETHEUS study ❗️ In ♂️ w/ HR Pca receiving ☢️(46/23 + 19-20/2 SBRT boost), G2+ GU tox assoc w/ 🔘 Prior TURP 🔘 Prostatic urethra length 🔘 Urethra PRV volume 🔘 Bladder D10cc and D15cc #pcsm #radonc - tinyurl.com/3efsntx5
Teaching Case: What are the outcomes after SBRT for urothelial ca of a transplanted kidney? After 13 mo, ☢️(40/5) to transplanted kidney associated w: 🔘❌ early/late adverse events 🔘✅ local control 🔘✅ stable eGFR RT planning + constraints reviewed:…
❗️ STELLAR-303 zanzalintinib + atezolizumab vs regorafenib in MSS CRC is “positive” for OS More specific data here is pending publication; can we add to CRT for MSS rectal cancer to improve organ preservation? @NiuSanford @KrishanJethwa ir.exelixis.com/news-releases/…
For dMMR colon cancer, FOLFOX + atezolizumab per ATOMIC is now incorporated into the NCCN Guidelines. @MayoCancerCare @ALLIANCE_org @ASCOPost @CCAlliance @RueschCenter @FightCRC
Please take a moment to read this blog on the recently activated NRG-GI011 trial in locally advanced #PancreaticCancer ! 👇
Thank you so much, Simul Parikh, for this excellent blog post on NRG GI-011, which explains our study rationale & logistics perfectly. We hope our trial is of interest to academic practices, community sites, & everything in between V grateful for your support🙏 Full link below
🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, @NRGonc for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏
The Department of Surgery at @MayoClinic is hiring a board-eligible/board-certified #Colorectal surgeon to join our surgical team at @MayoClinic in Rochester. Interested individuals can learn more about the role and apply here: jobs.mayoclinic.org/job/rochester/…
The question is really in patients who are progressing, where is this happening? 43/89 = 0.483 about half involve locoregional failure. So there is still needed room here for locoregional improvement!
🚨ESOPEC, Patterns of Recurrence🚨 🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%) ⚠️Locoregional Recurrence Remains notable (~20%) 🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation #ASCO25
🔥SPRING-01🔥 While ICI efficacy has been debatable in pMMR CRC, here are a few additional trials showing that addition of ICI to RT--> chemo can augment response STELLAR-II (Sintilimab) (attached image) UNION (Camrelizumab): annalsofoncology.org/article/S0923-… TORCH (Toripalimab):…
🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25
The OncoAlert🚨 RoundUp DAY THREE #ASCO25 👉REGISTER HERE OncoAlert360.com OR buff.ly/p0O1gZ8 FOR A MORE COMPLETE VIEW of the TOP of DAY 3 of the congress JOIN THE NEWSLETTER Discussing: ✅CHALLENGE: Excercise & adj Chemo #ColonCancer ✅MATTEHHORN: in…
#ASCO25 What does >10 MET-hrs/week actually look like and how can we break it down for patients? That was the CHALLENGE trial target —and it delivered a DFS HR of 0.72. But this isn’t just a number. It’s a prescription. 💡 1 MET = resting energy 10 MET-hrs/week = 150–300 min of…
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…
Dr @YJanjigianMD presents the updated data from #MATTERHORN 🗻 met its primary end point of improved #EFS and #OS #GIonc for plenary at #ASCO25 @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @drenriquegrande @FunchainMD @MKnoll_MD @bavilima @KrishanJethwa…
1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?
🚨ATOMIC🚨 🔍Resected Stage 3 dMMR Colon Cancer N= 712 👉🏼FOLFOX +- Atezolizumab 🔥Atezolizumab Demonstrated: ✅⬆️DFS (3yr 86% vs 77%, HR 0.5, p<.0001) 🔥A new standard option! 🙌🏼Congrats @FASinicropeMD @MayoCancerCare Next step-Is the FOLFOX (or surgery) needed❓ #ASCO25
